Xenon Pharmaceuticals (XENE) Research & Development (2013 - 2026)
Xenon Pharmaceuticals (XENE) reported Research & Development of $88.5 million for Q1 2026, up 44.62% year-over-year from $61.2 million in Q1 2025, and up 0.92% quarter-over-quarter from $87.7 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Research & Development (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 14 years of Research & Development data on file, last reported at $88.5 million in Q1 2026.
- Research & Development for Q1 2026 came in at $88.5 million, up 44.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $328.2 million (up 44.38% YoY), and the FY2025 annual result was $300.9 million, up 43.04% from the prior year.
- Research & Development improved to $88.5 million in Q1 2026 per XENE's latest filing, from $87.7 million in the prior quarter.
- Over five years, Research & Development peaked at $88.5 million in Q1 2026 and troughed at $19.4 million in Q1 2022.
- A 5-year average of $51.4 million and a median of $44.2 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development jumped 104.11% in 2023, then advanced 11.98% in 2024.
- A 5-year view of Research & Development shows it stood at $34.8 million in 2022, then increased by 17.93% to $41.1 million in 2023, then jumped by 44.79% to $59.5 million in 2024, then surged by 47.46% to $87.7 million in 2025, then increased by 0.92% to $88.5 million in 2026.
- Business Quant data shows XENE's Research & Development at $88.5 million in Q1 2026, $87.7 million in Q4 2025, and $77.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Xenon Pharmaceuticals | 4.61 Bn | 4.61 Bn | - | 88.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 88.51 Mn |
| Dec 31, 2025 | 87.70 Mn |
| Sep 30, 2025 | 77.05 Mn |
| Jun 30, 2025 | 74.99 Mn |
| Mar 31, 2025 | 61.20 Mn |
| Dec 31, 2024 | 59.47 Mn |
| Sep 30, 2024 | 56.97 Mn |
| Jun 30, 2024 | 49.70 Mn |
| Mar 31, 2024 | 44.25 Mn |
| Dec 31, 2023 | 41.08 Mn |
| Sep 30, 2023 | 42.88 Mn |
| Jun 30, 2023 | 44.04 Mn |
| Mar 31, 2023 | 39.52 Mn |
| Dec 31, 2022 | 34.83 Mn |
| Sep 30, 2022 | 29.43 Mn |
| Jun 30, 2022 | 22.15 Mn |
| Mar 31, 2022 | 19.36 Mn |
| Dec 31, 2021 | 21.89 Mn |
| Sep 30, 2021 | 18.89 Mn |
| Jun 30, 2021 | 18.38 Mn |